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Protein tyrosine phosphatase receptor type D (PTPRD) is a putative tumor suppressor in
several cancers including head and neck squamous cell carcinoma (HNSCC). STAT3 is a
frequently hyperactivated oncogene in HNSCC. As STAT3 is a direct substrate of PTPRD,
we sought to determine the genetic or epigenetic alterations of PTPRD that contribute to
overactive STAT3 in HNSCC.
Methods
We analyzed data from The Cancer Genome Atlas (TCGA) and our previous whole-exome
sequencing study and summarized the mutation, methylation, and copy number status of
PTPRD in HNSCC and other cancers. In vitro studies involved standard transfection and
MTT protocols, as well as methylation-specific PCR.
Results
Our findings indicate that PTPRDmutation, rather than methylation or copy number alteration,
is the primary mechanism by which PTPRD function is lost in HNSCC.We demonstrate that
overexpression of wild-type PTPRD in HNSCC cells significantly inhibits growth and STAT3
activation while PTPRDmutants do not, suggesting that mutation may lead to loss of function
and subsequent hyper-phosphorylation of PTPRD substrates, especially STAT3. Importantly,
we determined that HNSCC cells harboring an endogenous PTPRDmutation are more sensi-
tive to STAT3 blockade than PTPRDwild-type cells. We additionally found that PTPRD
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mRNA expression does not correlate with pSTAT3 expression, suggesting that alterations
that manifest through altered mRNA expression, including hypermethylation and gene copy
number alterations, do not significantly contribute to STAT3 overactivation in HNSCC.
Conclusion
PTPRDmutation, but not methylation or copy number loss, may serve as a predictive bio-
marker of sensitivity to STAT3 inhibitors in HNSCC.
Introduction
Protein tyrosine phosphatase receptor type D (PTPRD) is a member of the receptor-type pro-
tein tyrosine phosphatase (PTPR) family. PTPRs are membrane-integral enzymes that catalyze
the removal of phosphate groups from specific proteins, thereby impacting cell signaling. Dysre-
gulation of PTPR signaling by genetic and/or epigenetic mechanisms may therefore ultimately
lead to cancerous phenotypes. [1] Several PTPR family members, including PTPRD, have been
reported to function as tumor suppressors where loss of function alterations may drive tumor
growth. [2,3] Genetic events including mutation, gene deletion, or epigenetic silencing may lead
to decreased phosphatase activity of PTPRs and enhanced oncogenic signaling. [1]
We recently reported the cumulative mutation profile of the PTPR gene family in cancer
with a focus on PTPRTmutation leading to STAT3 activation in head and neck squamous cell
carcinoma (HNSCC). [4] Our analysis revealed that 15 solid tumor types harbored mutations of
at least one PTPR gene. PTPRD is one of the most commonly mutated PTPR family members in
HNSCC, and PTPRD has been reported to function as a tumor suppressor in this malignancy.
[5] PTPRD is also mutated, deleted, or hyper-methylated in glioblastoma (GBM), while the gene
is unmethylated and expressed in normal brain tissue. [6] Furthermore, PTPRDmutations were
found to be associated with increased expression of phosphorylated STAT3, a direct PTPRD
substrate, in GBM. In addition to GBM, 13% and 25% of HNSCC tumors analyzed in the above
study harbored PTPRDmutation or promoter methylation, respectively. Homozygous deletion
of PTPRD has additionally been reported in laryngeal cancer, suggesting that genetic aberrations
affecting PTPRD function may be a common event across many cancers. [5]
These cumulative findings led us to hypothesize that genetic and/or epigenetic alteration of
PTPRDmay contribute to enhanced signaling and growth in HNSCC where key components
of the pathway may serve as plausible therapeutic targets. Here, we summarize the genetic and
epigenetic profile of PTPRD in HNSCC from The Cancer Genome Atlas (TCGA) and our
prior HNSCC mutational landscape study. [7] We then tested the consequences of PTPRD
alterations found in human HNSCC tumors in relevant preclinical models to assess STAT3
activity and sensitivity to STAT3 inhibition.
Materials and Methods
Cell culture, drug treatment, and transfection
All HNSCC cell lines were genotypically verified as previously described. [4] Cal27 cells were
obtained from ATCC (Manassas, VA). PE/CA-PJ34clone12 and PE/CA-PJ49 cells were
obtained from Sigma-Aldrich (St. Louis, MO). 686LN cells were obtained from Georgia Chen
at MD Anderson Cancer Center (Houston, TX). Cal27 cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM) (Mediatech, Inc., Manassas, VA) supplemented with 10% fetal
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bovine serum (FBS) (Gemini Bio-Products, West Sacramento, CA). 686LN cells were cultured
in DMEM/F12 (Life Technologies, Grand Island, NY) supplemented with 10% FBS. PE/
CA-PJ34clone12 and PE/CA-PJ49 were cultured in Iscove's Modification of DMEM (Media-
tech Inc., Manassas, VA) supplemented with 10% FBS and 2 mM L-glutamine (Life Technolo-
gies, Grand Island, NY). All cells were maintained in an incubator at 37°C and 5% CO2. JSI-
124 (Calbiochem, Billerica, MA) was dissolved in DMSO. Transfection was performed with
Lipofectamine 2000 (Life Technologies, Grand Island, NY) or FuGENE HD (Promega Corpo-
ration, Madison, WI) according to the manufacturer’s instructions with 4 μg DNA diluted in
Opti-MEM (Life Technologies, Grand Island, NY).
Site-directed mutagenesis
PTPRDmutations (K1502M, S384R, T1100M and L1147F) were generated from the wild-type
plasmid using the Phusion site-directed mutagenesis kit (Thermo Fisher Scientific, Waltham,
MA) following the manufacturer’s protocol and confirmed by Sanger sequencing. Plasmid
amplifications were performed using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Ger-
many) or the Hurricane Maxi Prep Kit (GerardBIOTECH, Oxford, OH) according to the man-
ufacturer’s instructions.
Immunoblotting
Primary antibodies for pSTAT3 (Y705) and STAT3 were obtained from Cell Signaling Tech-
nology (Danvers, MA). β-tubulin primary antibody was purchased from Abcam (Cambridge,
MA). Secondary antibodies were purchased from BioRad (Hercules, CA). Blots were quanti-
tated by densitometry using ImageJ software.
MTT assay
MTT assays were performed by incubating cells in 5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5
diphenyl tetrazolium bromide in PBS at for 30 min at 37°C and 5% CO2. After incubation, the
solution was aspirated and replaced with DMSO. Absorbance of this solution was measured at
570 nm on a spectrophotometer.
Methylation-specific PCR
Tumor and normal tissue were obtained under the auspices of an Institutional Review Board-
approved protocol at the University of Pittsburgh. DNA was isolated from formalin-fixed par-
affin embedded tissue using the QIAamp DNA FFPE Tissue Kit, and cell line DNA was isolat-
ing using the QIAamp DNAMini Kit. Bisulfite conversion was performed using the EpiTect
Bisulfite Kit and methylation-specific polymerase chain reaction (MSP) was conducted using
EpiTect MSP Kit. All kits were used according to the manufacturer’s instructions (Qiagen, Hil-
den, Germany). MSP primers were designed using MethPrimer software. [8] For methylation,
the forward and reverse primer sequences were GTTTTATTTTGGATTTTTGGAATC and
TACCTAACGCGACCTAAACG, respectively. For unmethylation, the forward and reverse primer
sequences were TATTTTGGATTTTTGGAATTGT and AACTACCTAACACAACCTAAACAAA,
respectively. Primers were specific for the intended methylation status as determined using the
EpiTect Control DNA Set (Qiagen, Hilden, Germany).
Data download and analysis
Mutation, copy number alteration, and RNA-Seq data were aggregated from the cBio Portal
[9,10] and published reports. [6,7,9] DNAmethylation data were obtained through the TCGA
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data matrix (https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm). DNA and protein
sequences and domain annotations were obtained from the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov). Reverse phase protein array data were obtained
from The Cancer Proteome Atlas (http://app1.bioinformatics.mdanderson.org/tcpa/_design/
basic/index.html). Statistical tests were performed using GraphPad Prism 5 software (Graph-
Pad, La Jolla, CA).
Trypan Blue Exclusion
PE/CA-PJ34clone12 cells were plated on 6-well plates at 100,000 cells per well. After 24 hours,
cells were transfected with vector control, wild-type PTPRD, or PTPRD mutants in triplicate
using 4 μg of plasmid DNA, 12 μL FuGENE HD (Promega Corporation, Madison, WI), and
200 μL Opti-MEM (Life Technologies, Grand Island, NY) per well added directly to wells con-
taining 3 mL complete medium. After 72 hours, cells were trypsinized and resuspended in PBS
containing 0.2% trypan blue (MP Biomedicals, LLC, Santa Ana, CA). Each cell suspension was
counted in four fields on a hemacytometer and the average was used to calculate the total num-
ber of cells present.
Results
PTPRDmutations occur frequently in HNSCC and other cancers
Somatic mutation is a common event leading to altered gene and protein function in cancer.
Eighteen non-synonymous PTPRDmutations have been identified to date in HNSCC tumors.
[6,7,9,10] These mutations appear scattered throughout the gene and protein sequence. (Fig
1A) They are all non-recurrent, with each occurring in a single HNSCC tumor, suggesting that
these are likely be loss-of-function mutations. Of these 18 mutations, 12 occur in the extracellu-
lar domain, 1 is localized to the catalytic domain, and 5 are in the transmembrane region
where no conserved domain has been identified. In addition to HNSCC, PTPRDmutations are
also widely observed in other cancer types. (Fig 1B) In The Cancer Genome Atlas (TCGA) col-
lection, PTPRD is most frequently mutated in cutaneous melanoma (59/344 cases, 17.2%), fol-
lowed by lung adenocarcinoma (33/230 cases, 14.3%), and stomach adenocarcinoma (30/289
cases, 10.4%). [9,10] As in HNSCC, PTPRDmutations in these cancers do not appear to cluster
into hotspot regions or residues, suggesting that loss of PTPRD function by somatic mutation
is a common event across multiple cancer sites.
The only mutation detected in HNSCC that has been previously identified in another cancer
is T1100M, which was reported in chronic lymphocytic leukemia. [11] Interestingly, several
other mutation sites found in HNSCC have a different amino acid substitution reported in
other cancers. For example, while K204E is observed in HNSCC, K204Q has been reported in
esophageal cancer. [12] In addition, a review of the COSMIC database (http://cancer.sanger.ac.
uk/cancergenome/projects/cosmic/) demonstrates detection of L503V in liver cancer (com-
pared to L503I in HNSCC) and L1036M in colon adenocarcinoma (compared to L1036P in
HNSCC). Ding et al additionally reported a mutation at this site (L1036Q) in lung adenocarci-
noma. [13] Interestingly, while K1502M is the only catalytic domain mutation identified to
date in HNSCC, TCGA has identified a K1502 nonsense mutation in lung adenocarcinoma.
Together, these findings suggest that while the specific PTPRDmutations found to date in
HNSCC are unique, the amino acid sites at which they occur may represent important residues
that are susceptible to genetic alterations. Indeed, multiple sequence alignment analysis indi-
cates that these residues are highly conserved across species, suggesting they may have a critical
role in proper PTPRD function (analysis not shown).
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HNSCC-derived PTPRDmutants lead to increased cell growth
PTPRD has been reported to serve as a tumor suppressor in human cancer. [3,5,6] To deter-
mine the functional consequences of PTPRDmutation in HNSCC, we generated several repre-
sentative HNSCC-derived PTPRD mutants by site-directed mutagenesis, including one
mutation in the extracellular domain (S384R), one in the catalytic domain (K1502M), and two
in the transmembrane region (T1100M and L1147F). Transient overexpression of these con-
structs in a HNSCC cell line with no endogenous PTPR family mutations (PE/CA-PJ34-
clone12) revealed that all of the PTPRD mutants tested led to increased growth as determined
by MTT assay relative to PTPRD wild-type-transfected cells. (Fig 2A) MTT assay results were
further confirmed with representative mutants by trypan blue exclusion assay in PE/CA-PJ34-
clone12 cells (Fig 2B). Collectively, these results suggest that PTPRDmutations inactivate the
tumor suppressive function of PTPRD irrespective of their localization throughout the gene,
leading to increased growth/proliferation in HNSCC cells.
Fig 1. PTPRDmutations are common in HNSCC and other cancers. (A) Localization of PTPRD protein mutations reported in HNSCC tumors. Red:
TCGA tumors [9,10]; Green: from [6]; Blue: from [7]. IG, Immunoglobulin; IG2, Second immunoglobulin (Ig)-like domain of the receptor protein tyrosine
phosphatase (RPTP)-F; FN3, Fibronectin type 3 domain; PTPc, Protein tyrosine phosphatase, catalytic domain. (B) Frequency of PTPRDmutations in
human cancers as determined by TCGA, with HNSCC shown in red.
doi:10.1371/journal.pone.0135750.g001
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PTPRDmutation is associated with increased pSTAT3 expression
STAT3 is hyper-activated by constitutive phosphorylation of tyrosine 705 (Y705) in many can-
cer types, including HNSCC. [14,15] Importantly, pSTAT3 (Y705) is a known direct substrate
of PTPRD. [6] To determine the effect of PTPRDmutation on STAT3 phosphorylation in
HNSCC, we first examined 200 HNSCC tumors with both whole exome sequencing and RPPA
analyses performed by TCGA and The Cancer Proteome Atlas (TCPA). HNSCC tumors with
non-synonymous PTPRDmutations express significantly higher levels of pSTAT3 (Y705) rela-
tive to tumors with wild-type PTPRD (Fig 3A). Notably, PTPRD is the only PTPR family mem-
ber for which this correlation is observed. To test the association between PTPRDmutation
and pSTAT3 expression directly, we transfected an HNSCC cell line with known endogenous
PTPRDmutation (Cal27 harboring mutation S387L) with wild-type PTPRD or vector control
and found that overexpression of wild-type PTPRD leads to significantly decreased pSTAT3
expression (P 0.05). (Fig 3B and 3C) Furthermore, overexpression of mutant PTPRD in
HNSCC cells without endogenous PTPR family mutations (PE/CA-PJ34clone12) leads to
increased pSTAT3 (Y705) expression relative to PTPRD wild-type-overexpressing cells for
nearly all mutations tested. (Fig 3D and 3E) Together, these results demonstrate that PTPRD
mutation leads to increased STAT3 signaling in HNSCC cells and tumors.
HNSCC cells with endogenous PTPRDmutation are more sensitive to
STAT3 pathway inhibition
Since PTPRDmutations increase STAT3 activation in HNSCC, we next sought to determine if
PTPRDmutation leads to increased sensitivity to STAT3 pathway inhibition. To test our
Fig 2. HNSCC-derived PTPRDmutations lead to increased cell growth/proliferation in HNSCC cells. (A) Cell growth was assessed by MTT assay 48
hrs after transfection and normalized to vector-transfected controls. One-way ANOVA P = 0.0007. Depicted P values represent the results of pairwise two-
tailed unpaired t tests. The experiment was performed three times with similar results. (B) Cell proliferation was assessed by trypan blue exclusion assay 72
hrs after transfection. One-way ANOVA P < 0.0001. Depicted P values represent the results of pairwise two-tailed unpaired t tests.
doi:10.1371/journal.pone.0135750.g002
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hypothesis, we employed HNSCC cells that harbor an endogenous PTPRDmutation (PE/
CA-PJ49). Treatment with the JAK/STAT inhibitor JSI-124 revels that these PTPRDmutant
cells exhibit enhanced sensitivity relative to PTPR family wild-type cells (PE/CA-PJ34clone12),
suggesting that PTPRDmutation may serve as a predictive biomarker for response to STAT3
pathway inhibitors (Fig 4).
Fig 3. PTPRDmutation is associated with increased pSTAT3 (Y705) expression in HNSCC tumors and cell lines. (A) HNSCC tumors harboring
PTPRDmutations express increased pSTAT3 (Y705) relative to PTPRDwild-type tumors as determined by whole exome sequencing and reverse-phase
protein array (RPPA). Two-tailed unpaired t test. (B) Overexpression of wild-type PTPRD in a PTPRD-mutant cell line (Cal27) leads to decreased pSTAT3
(Y705) expression (C) Quantitation of three replicate experiments as shown in B. Two-tailed unpaired t test. (D) PTPRD-wild-type HNSCC cells (PE/
CA-PJ34clone12) transiently overexpressing mutant PTPRD exhibit increased pSTAT3 (Y705) expression relative to wild-type-expressing cells. (E)
Quantitation of three replicate experiments as shown in D. Two-tailed unpaired t test.
doi:10.1371/journal.pone.0135750.g003
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PTPRDmRNA expression does not correlate with pSTAT3 expression
Promoter hypermethylation and gene copy number loss represent two additional mechanisms
that may lead to loss of function of PTPRD via downregulation of mRNA expression. Impor-
tantly, PTPRDmRNA expression does not correlate with pSTAT3 expression in TCGA
HNSCC samples, suggesting that methylation and copy number loss do not significantly con-
tribute to STAT3 overactivation in HNSCC (S1A Fig). Indeed, a more detailed analysis reveals
that while PTPRDmethylation does correlate with mRNA expression as would be expected for
any gene (S1B Fig), we observe no correlation between methylation and pSTAT3 expression
(S1C Fig), nor do we observe any instances of aberrant promoter hypermethylation (defined
here as a methylation level greater than three standard deviations above the mean methylation
of the same genetic locus in organ-matched normal samples). In order to validate these find-
ings, we performed methylation-specific PCR on an independent cohort of HNSCC tumors
and found evidence of PTPRD promoter methylation in 75% of tumors analyzed (30/40) (rep-
resentative analysis in S2 Fig). Importantly, we also observed PTPRD promoter methylation in
five paired normal oral mucosa samples from these HNSCC patients (S3 Fig), further suggest-
ing that the PTPRDmethylation observed in HNSCC is not tumor-specific.
PTPRD copy number alterations occur to a substantial degree in HNSCC and other cancers
(Fig 5A), where gene copy loss, particularly heterozygous loss, occurs more frequently than
gain in HNSCC and all cancers analyzed with the exception of colorectal and cervical cancers.
Importantly, we do not observe a significant correlation between copy number alterations and
mRNA expression in HNSCC (Fig 5B). Together, these findings suggest that promoter
Fig 4. HNSCC cells harboring an endogenous PTPRDmutation (PE/CA-PJ49) are more sensitive to the STAT3 pathway inhibitor JSI-124 relative to
representative PTPRDWTHNSCC cells (PE/CA-PJ34clone12). Cells were treated with increasing concentrations of JSI-124 for 24 hours followed by
MTT assay. The experiment was performed three times with similar results.
doi:10.1371/journal.pone.0135750.g004
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hypermethylation and gene copy number loss do not significantly contribute to STAT3 overac-
tivation in HNSCC.
Discussion
STAT3 is an oncogene that is hyper-activated in many cancers, including HNSCC, where
STAT3 hyper-activation is associated with decreased survival and emergent resistance to
EGFR-targeted therapy. [9,16,17] Potential mechanisms that may result in increased STAT3
activation in cancer include increased signaling through upstream receptor or non-receptor
tyrosine kinases such as EGFR and JAK, and/or inactivation of negative regulators of STAT3,
including protein tyrosine phosphatases. [18,19] We recently reported that the receptor-type
protein tyrosine phosphatase (PTPR) family is frequently mutated in HNSCC and other can-
cers and demonstrated that HNSCC-derived mutations of PTPRT induce STAT3 phosphoryla-
tion and drive HNSCC cell survival. [4] As PTPRD represents an additional receptor-like
phosphatase that directly targets STAT3, we sought to determine if genetic or epigenetic loss of
PTPRD function may contribute to STAT3 overactivation in HNSCC.
In the present study, we first identified 18 previously uncharacterized PTPRDmutations in
HNSCC tumors. These mutations are all non-recurrent and are located throughout gene, a pat-
tern that is consistent with that generally observed for tumor suppressor genes. We have
shown that overexpression of wild-type PTPRD leads to growth suppression in HNSCC cells,
while overexpression of representative mutants does not, thus establishing a functional conse-
quence of PTPRDmutation in HNSCC models. These findings are consistent with those of pre-
vious in vitro studies across several cancer types, including glioblastoma, melanoma, colorectal
cancer, and neuroblastoma, where wild-type PTPRD has been observed to suppress colony for-
mation and cell growth as well as enhance apoptosis, while cancer-derived PTPRD mutants do
Fig 5. PTPRD copy number alterations are frequent across cancers but are not associated with PTPRDmRNA expression in HNSCC. (A) Copy
number alteration of PTPRD in human cancers as determined by TCGA. (B) PTPRD copy number alterations do not correlate with altered PTPRDmRNA
expression in HNSCC. A Jonckheere-Terpstra test was performed using StatXact software (Cytel, Cambridge, MA).
doi:10.1371/journal.pone.0135750.g005
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not. [3,6,20] These cumulative findings suggest that PTPRDmutations in cancer lead to loss of
its tumor suppressive function.
In order to determine if PTPRDmutation affects the activity of STAT3, a PTPRD substrate,
we analyzed TCGA and TCPA data and found that HNSCC tumors with PTPRDmutations
express significantly elevated pSTAT3 (Y705) relative to PTPRD-wild-type tumors. We previ-
ously reported a similar association between pSTAT3 (Y705) expression and mutation of a
group of putative PTPR tumor suppressor genes, including PTPRD. [4] When each gene is con-
sidered individually rather than as a group, PTPRD is the only PTPR family member for which
mutation is significantly associated with pSTAT3 (Y705) expression (S4 Fig). This result sug-
gests that while the number of tumors harboring a mutation in any single PTPR family member
may be insufficient to detect a significant difference in pSTAT3 (Y705) expression, PTPRD
mutation in particular is uniquely associated with an increase in pSTAT3 (Y705) expression
that is sufficiently large to detect statistical significance. Futhermore, overexpression of wild-
type PTPRD in HNSCC cell lines harboring endogenous PTPRDmutations leads to downregu-
lation of pSTAT3 (Y705), thus confirming that PTPRD regulates STAT3 activation in HNSCC
models. While wild-type PTPRD leads to downregulation of pSTAT3 (Y705) in HNSCC cells,
overexpression of most HNSCC-derived mutants does not alter pSTAT3 (Y705) expression
relative to vector control, suggesting that these mutations lead to loss of function, but not in a
dominant negative manner. In the case of the L1147F mutation tested herein, overexpression
in HNSCC cells leads to increased growth, but not increased pSTAT3 (Y705) expression (see
Figs 2A and 3D), indicating that certain mutations may lead to cancerous phenotypes in a
STAT3-independent manner. These mutations may manifest through alternate mechanisms
which may include extracellular interactions or alteration of relative affinities for alternate
enzymatic substrates.
As PTPRDmutation leads to increased STAT3 activation in HNSCC, we next tested
whether cells harboring a PTPRDmutation may be more sensitive to STAT3 pathway inhibi-
tion. Here we demonstrate that HNSCC cells with an endogenous PTPRDmutation are more
sensitive to the JAK/STAT inhibitor JSI-124 than HNSCC cells harboring no PTPR family
mutations, suggesting that HNSCC tumors with PTPRDmutations may be exquisitely sensitive
to STAT3 inhibitors that are currently in preclinical and clinical development. In order to
devise an optimal treatment strategy for HNSCC patients with PTPRDmutations, further
study of additional PTPRD-interacting proteins that may serve as therapeutic targets may be
warranted. In particular, PTPRDmutation may additionally confer sensitivity to aurora kinase
A inhibitors currently in clinical development, where aurora kinase A phosphorylation and sta-
bility are normally regulated by PTPRD. [3]
An additional mechanism by which PTPRD function may be lost is through mRNA downre-
gulation, including by promoter hypermethylation or gene copy number loss. First, we deter-
mined that PTPRDmRNA expression does not correlate with pSTAT3 expression in HNSCC,
suggesting that these mechanisms are not likely to significantly contribute to STAT3 overactiva-
tion in HNSCC. It should be noted that this analysis may be complicated by the several cases in
which little or no PTPRDmRNA was detected. Indeed, our overexpression studies in HNSCC
cells suggest that expression of PTPRD would be expected to impact pSTAT3 (Y705) expres-
sion. Nonetheless, this correlation has not emerged in the HNSCC tumors analyzed to date.
A more detailed analysis of these mechanisms next revealed that the PTPRD promoter is not
hypermethylated in HNSCC relative to organ-matched normal tissue, a finding we validated in
an independent cohort of HNSCC tumor and matched normal pairs by methylation-specific
PCR. The disparity between our present findings and previous reports of PTPRD promoter
methylation in HNSCC is likely due to the prior lack of comparison between tumor and normal
tissue. [6] The low level of PTPRD promoter methylation observed in HNSCC is additionally
PTPRDMutation Leads to STAT3 Activation and Inhibitor Sensitization
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not associated with altered pSTAT3 (Y705) expression, further suggesting that this event does
not significantly contribute to the cancer phenotype in HNSCC. A similar lack of aberrant
PTPRD promoter hypermethylation has also been reported in cutaneous squamous cell carci-
noma, suggesting this may be an uncommon event in multiple epithelial malignancies. [21]
Our analysis of TCGA data indicates that nearly half of HNSCC tumors harbor a copy num-
ber alteration of PTPRD and that copy number loss is more frequent than copy number gain in
HNSCC and across nearly all cancers analyzed. PTPRD homozygous or heterozygous deletion
has also been reported in cutaneous squamous cell carcinoma [21,22], GBM [6,20,23,24], lung
cancer [25,26], neuroblastoma [27], metastatic melanoma [28,29], squamous cell carcinoma of
the vulva [30], hepatocellular carcinoma [31], and laryngeal squamous cell carcinoma [5].
Importantly, no significant association was detected between PTPRD copy number alteration
and PTPRDmRNA expression in HNSCC, suggesting that copy number loss is not the primary
mechanism of loss of PTPRD function in HNSCC.
In conclusion, we have demonstrated herein that somatic mutation of PTPRD is the primary
mechanism by which PTPRD loss of function occurs in HNSCC. We propose that nearly all of
these mutations lead to loss of catalytic activity and hence reduced dephosphorylation of the
substrate pSTAT3 (Y705). While promoter methylation and copy number loss are detectable at
the PTPRD locus, these events are not associated with upregulation of pSTAT3 (Y705) expres-
sion. In contrast, somatic mutation of PTPRD leads to increased STAT3 activation in HNSCC
tumors and cell lines, concomitant with increased cell growth and sensitivity to STAT3 path-
way inhibition. These findings suggest that PTPRDmutation may represent a predictive bio-
marker for exquisite response to STAT3 targeted therapy in HNSCC.
Supporting Information
S1 Fig. PTPRD promoter methylation correlates with PTPRDmRNA expression but does
not correlate with pSTAT3 (Y705) expression in HNSCC. (A) PTPRDmRNA expression is
not significantly associated with pSTAT3 (Y705) expression. n = 172, Pearson r = 0.05157,
P = 0.5017, R2 = 0.002659. (B) PTPRD promoter methylation correlates with PTPRDmRNA
expression. n = 172, Pearson r = -0.5242, P< 0.0001, R2 = 0.2747. (C) PTPRD promoter meth-
ylation is not significantly associated with pSTAT3 (Y705) expression. n = 211, Pearson
r = 0.0008795, P = 0.9899, R2 = 7.735e-007.
(TIF)
S2 Fig. MSP analysis of representative HNSCC tumor samples.Methylation was observed in
30/40 (75%) HNSCC tumors analyzed. M denotes primers amplifying methylated sequences,
while U denotes primers amplifying unmethylated sequences.
(TIF)
S3 Fig. The PTPRD promoter is not hyper-methylated in HNSCC tumors compared with
adjacent normal mucosa. Five HNSCC tumors and matched normal mucosa from the same
patients were collected and analyzed by MSP. M denotes primers amplifying methylated
sequences, while U denotes primers amplifying unmethylated sequences.
(TIF)
S4 Fig. PTPRD is the only family member for which mutation is associated with pSTAT3
(Y705) expression in HNSCC.Whole exome sequencing and reverse-phase protein array data
reveal that no other PTPR family mutations are significantly associated with pSTAT3 (Y705). P
values represent the results of two-tailed unpaired t tests. N/A indicates insufficient sample size
for calculation.
(TIF)
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